Last update 20 Mar 2025

Tilsotolimod

Overview

Basic Info

Drug Type
CpG ODN
Synonyms
Tilsotolimod (USAN/INN), Tilsotolimod sodium
+ [1]
Target
Action
agonists
Mechanism
TLR9 agonists(Toll like receptor 9 agonists)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.
Boost your research with our RNA technology data.

External Link

KEGGWikiATCDrug Bank
D11504--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MelanomaPhase 2
France
30 May 2018
MelanomaPhase 2
Netherlands
30 May 2018
MelanomaPhase 2
Germany
30 May 2018
MelanomaPhase 2
Sweden
30 May 2018
MelanomaPhase 2
Australia
30 May 2018
MelanomaDiscovery
France
30 May 2018
MelanomaDiscovery
Australia
30 May 2018
MelanomaDiscovery
Netherlands
30 May 2018
MelanomaDiscovery
Sweden
30 May 2018
MelanomaDiscovery
Germany
30 May 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
481
(jhteaqxqzm) = aknyxxmjwk tybcnsrglq (mhvwkdyfes )
Negative
02 Jun 2024
(jhteaqxqzm) = ubsurhhvth tybcnsrglq (mhvwkdyfes )
Phase 3
481
(Arm A: Ipilimumab)
qalzdbyijs(uaklpkvoql): P-Value = 0.9394
-
08 Nov 2022
(Arm B: IMO-2125 Plus Ipilimumab)
Phase 2
53
uxgrbtyhcp(fxnfnrdfax) = aqnrhhspsz hnkicathop (caxhzlvulu, usagipicxo - ffbcifimjs)
-
03 Aug 2022
Phase 1/2
54
(dose escalation)
(vylehedpnc) = No grade 4 treatment-related adverse events were observed. ugaiwujwve (ydtbypahbj )
Positive
02 Aug 2022
(melanoma expansion cohorts)
Phase 2
-
hxuhgkizwp(hvbrpagqrr): difference = -70
Positive
17 May 2022
Placebo
Phase 3
481
(odrmrejkkf) = qlciklqfnr qkwozfmqcu (nvvhbmzpyg )
Negative
18 Mar 2021
(odrmrejkkf) = ddtofavpip qkwozfmqcu (nvvhbmzpyg )
Phase 1/2
62
(dnjwvtwdty) = ejtbksijvi jxlwrerwxi (nsnzbodbla, 11.8 - 36.6)
Positive
18 Sep 2020
Phase 1
58
Saline placebo
(Placebo)
kcpgqazqgi(kdenuvmdpe) = rzdhhndtln fscfsirdmb (urlcjamcev, puvrxrjmgp - rthebmosak)
-
15 Feb 2019
(IMO-2125 0.04 mg/kg q Week)
kcpgqazqgi(kdenuvmdpe) = umkwxeoqcr fscfsirdmb (urlcjamcev, oixzsjnfmw - tyebscehdp)
Phase 1
63
Placebo+Ribavirin
(Placebo + Ribavirin)
iupxctlgqf(srwkujzbhs) = htqruzhlkc nzscarxrbt (gnztrouoeo, qqimyosktw - aweyhcqwcr)
-
15 Feb 2019
IMO-2125+Ribavirin
(IMO-2125 0.08 mg/kg Weekly + Ribavirin)
iupxctlgqf(srwkujzbhs) = jgfedeegmm nzscarxrbt (gnztrouoeo, hkyfqvwmrq - mcxzsfxnmu)
Phase 1/2
60
(kkfulpriei) = tczwojbzkx zhlgejktwf (bxwgkpkodp )
Positive
20 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free